0000000000919355

AUTHOR

Stefan Kanzler

showing 4 related works from this author

Mini-Laparoscopically Guided Percutaneous Gastrostomy and Jejunostomy

2003

Abstract Background: Percutaneous endoscopic tube placement can be problematic under certain circumstances: absence of transillumination of the abdominal wall, percutaneous jejunostomy in patients with a PEG tube and recurrent aspiration, enteral feeding access after gastrectomy, and obstruction of the upper GI tract. As an alternative in these problematic situations, a technique was developed for placing feeding tubes under visual control by using mini-laparoscopy. Methods: Placement of a feeding tube with mini-laparoscopy with the patient under conscious sedation was considered for 17 patients in whom standard PEG placement was impossible. Techniques used were the following: combined mini…

AdultMaleEnteroscopymedicine.medical_specialtyPercutaneousmedicine.medical_treatmentConscious SedationJejunostomyEnteral NutritionmedicineHumansIntubationRadiology Nuclear Medicine and imagingIntubation GastrointestinalFeeding tubeAgedGastrostomymedicine.diagnostic_testbusiness.industryGastroenterologyMiddle AgedGastrostomySurgeryEndoscopyJejunostomyFemaleLaparoscopybusinessPercutaneous Endoscopic TubeGastrointestinal Endoscopy
researchProduct

Efficacy of an escalating dose regimen of pegylated interferon ?-2a plus ribavirin in the early phase of HCV reinfection after liver transplantation

2007

We evaluated the safety and efficacy of an escalating dose regimen of pegylated interferon alpha-2a (PEG-IFN(alpha-2a)) and ribavirin in the early phase of recurrent hepatitis C after orthotopic liver transplantation (OLT). In this prospective study, 26 patients transplanted for hepatitis C virus cirrhosis with recurrent hepatitis C were treated 3.4 +/- 3.6 months after OLT and compared with an untreated historical control. PEG-IFN(alpha-2a) was initiated as monotherapy, following stepwise dose escalation up to 180 mug/week and the addition of ribavirin up to 1200 mg/day or maximally tolerated doses for 48 weeks. In the intent-to-treat analysis, 38% showed an early virological response (EVR…

Liver CirrhosisMalemedicine.medical_specialtyCirrhosisHepatitis C virusmedicine.medical_treatmentHepacivirusLiver transplantationInterferon alpha-2medicine.disease_causeGastroenterologyAntiviral AgentsPolyethylene GlycolsCohort Studieschemistry.chemical_compoundPostoperative ComplicationsPegylated interferonRecurrenceInternal medicineRibavirinmedicineHumansAdverse effectAgedTransplantationbusiness.industryRibavirinInterferon-alphaAlanine TransaminaseHepatitis CMiddle Agedmedicine.diseaseHepatitis CRecombinant ProteinsLiver TransplantationRegimenTreatment OutcomechemistryImmunologyRNA ViralFemalebusinessmedicine.drugTransplant International
researchProduct

Gemcitabine plus sorafenib versus gemcitabine alone in advanced biliary tract cancer: a double-blind placebo-controlled multicentre phase II AIO stud…

2014

Background: Since sorafenib has shown activity in different tumour types and gemcitabine regimens improved the outcome for biliary tract cancer (BTC) patients, we evaluated first-line gemcitabine plus sorafenib in a double-blind phase II study. Patients and methods: 102 unresectable or metastatic BTC patients with histologically proven adenocarcinoma of gallbladder or intrahepatic bile ducts, Eastern Cooperative Oncology Group (ECOG) 0–2 were randomised to gemcitabine (1000 mg/m2 once weekly, first 7-weeks + 1-week rest followed by once 3-weeks + 1-week rest) plus sorafenib (400 mg twice daily) or placebo. Treatment continued until progression or unacceptable toxicity. Tumour samples were p…

OncologyMaleCancer ResearchAdvanced biliary tract cancerPDGFRβPhases of clinical researchHif1αKaplan-Meier Estimateurologic and male genital diseasesGastroenterologyDeoxycytidineMetastasisAntineoplastic Combined Chemotherapy Protocolsheterocyclic compoundsProspective StudiesLymph nodeAged 80 and overVascular Endothelial Growth FactorsMiddle AgedSorafenibBTCfemale genital diseases and pregnancy complicationsmedicine.anatomical_structureBiliary Tract NeoplasmsTreatment OutcomeOncologyAdenocarcinomaFemaleGallbladder NeoplasmsHand-Foot Syndromemedicine.drugSorafenibAdultNiacinamidemedicine.medical_specialtyPlaceboDisease-Free SurvivalDrug Administration ScheduleDouble-Blind MethodInternal medicinemedicineBiomarkers TumorHumansddc:610neoplasmsAgedbusiness.industryGallbladderPhenylurea Compoundsmedicine.diseaseVascular Endothelial Growth Factor Receptor-2Gemcitabinedigestive system diseasesGemcitabineChemokine CXCL12VEGFR-3VEGFR-2Bile Ducts IntrahepaticBile Duct Neoplasmsc-kitQuality of LifebusinessEuropean journal of cancer (Oxford, England : 1990)
researchProduct

Prospective Randomized Comparison of Minilaparoscopy and Percutaneous Liver Biopsy

2007

Liver cirrhosis represents an advanced stage of hepatic fibrosis characterized by distortion of organ architecture and formation of regenerative nodules. Retrospective series reported percutaneous liver biopsy to miss cirrhosis in about 30%. The aim of this study was to prospectively compare diagnostic sensitivity regarding the detection of cirrhosis and the complication rates of percutaneous versus minilaparoscopic liver biopsy in chronic liver disease.Eight hundred fifty-seven patients were randomized to percutaneous (415) or to minilaparoscopic liver biopsy (442). Macroscopic liver evaluation was documented as normal, fibrosis, or cirrhosis. Liver specimens were assessed blindly accordin…

AdultLiver CirrhosisMalemedicine.medical_specialtyCirrhosisBiopsyDiagnosis DifferentialBiopsymedicineHumansProspective StudiesProspective cohort studyLaparoscopymedicine.diagnostic_testbusiness.industryGastroenterologyMiddle AgedPrognosismedicine.diseaseSurgeryLiverLiver biopsyChronic DiseaseFemaleLaparoscopyHistopathologyRadiologyGastrointestinal HemorrhageHepatic fibrosisComplicationbusinessFollow-Up StudiesJournal of Clinical Gastroenterology
researchProduct